Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 9/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575051 | 0.79 | GAA (0.50) | GAASMN1; SMN2TSHRPLA2G7MEN1 | |
| SCHEMBL575048 | 0.78 | SMN1; SMN2 (0.41) | GAASMN1; SMN2TSHRNPC1HTT | |
| SCHEMBL585622 | 0.74 | TSHR (0.45) | GAASMN1; SMN2TSHRPLA2G7MEN1 | |
| SCHEMBL14865566 | 0.70 | TSHR (0.34) | GAASMN1; SMN2TSHRMEN1LMNA | |
| SCHEMBL14308133 | 0.69 | CHRNA7 (0.56) | GAASMN1; SMN2TSHRMEN1LMNA | |
| SCHEMBL20749289 | 0.68 | TSHR (0.55) | GAASMN1; SMN2TSHRPLA2G7MEN1 | |
| SCHEMBL1562625 | 0.67 | TSHR (0.56) | GAASMN1; SMN2TSHRPLA2G7MEN1 | |
| SCHEMBL15580643 | 0.65 | SMN1; SMN2 (0.38) | GAASMN1; SMN2TSHRMEN1LMNA | |
| SCHEMBL1711026 | 0.65 | SMN1; SMN2 (0.43) | GAASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL10144466 | 0.65 | SMN1; SMN2 (0.51) | GAASMN1; SMN2TSHRPLA2G7NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2581374-B1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | INST PHARM & TOXICOLOGY AMMS (CN) | 2014-03-19 | — | — | EP | claimed |
| EP-2581374-A1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2013-04-17 | — | — | EP | claimed |
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A.CHINA (CN) | 2012-05-17 | — | — | US | claimed |
| EP-2417973-A1 | SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Ý4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2012-02-15 | — | — | EP | claimed |
| US-9149467-B2 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A. CHINA (CN) | 2015-10-06 | — | — | US | disclosed |
| US-8703952-B2 | Synthesis of 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline and analogues and intermediates | WISTA LABORATORIES LTD. (SG) | 2014-04-22 | — | — | US | disclosed |
| EP-2581374-B1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | INST PHARM & TOXICOLOGY AMMS (CN) | 2014-03-19 | — | — | EP | disclosed |
| EP-2417973-B1 | SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO [4, 3-B]INDOLE DERIVATIVE | INST PHARM & TOXICOLOGY AMMS (CN) | 2013-08-28 | — | — | EP | disclosed |
| EP-2581374-A1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2013-04-17 | — | — | EP | disclosed |
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A.CHINA (CN) | 2012-05-17 | — | — | US | disclosed |
| EP-2417973-A1 | SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Ý4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2012-02-15 | — | — | EP | disclosed |
| US-20110245504-A1 | SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-y-CARBOLINE AND ANALOGUES AND INTERMEDIATES | WISTA LABORATORIES LTD. | 2011-10-06 | — | — | US | disclosed |
| WO-2010067085-A2 | SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-Υ-CARBOLINE AND ANALOGUES AND INTERMEDIATES | WISTA LABORATORIES LTD. (SG) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | HTT, HTR5A, HTR3B | GAA 3762/4885SMN1; SMN2 113/4885TSHR 3140/4885 |
| US-20110245504-A1 | SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-y-CARBOLINE AND ANALOGUES AND INTERMEDIATES | DDT, CYP2J2, CYP1B1 | GAA 2943/4885SMN1; SMN2 4299/4885TSHR 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.